Effectiveness of Omicron XBB.1.5 vaccine against infection with SARS-CoV-2 Omicron XBB and JN.1 variants, prospective cohort study, the Netherlands, October 2023 to January 2024-Reference-Cited by-同舟云学术

Effectiveness of Omicron XBB.1.5 vaccine against infection with SARS-CoV-2 Omicron XBB and JN.1 variants, prospective cohort study, the Netherlands, October 2023 to January 2024

Published:2024-03-07 Issue:10 Volume:29 Page:
ISSN:1560-7917
Container-title:Eurosurveillance
language:en
Short-container-title:

Author:

Huiberts Anne J¹,Hoeve Christina E¹,de Gier Brechje¹,Cremer Jeroen¹,van der Veer Bas¹,de Melker Hester E¹,van de Wijgert Janneke HHM²¹,van den Hof Susan¹,Eggink Dirk³¹,Knol Mirjam J³¹

Affiliation:

1. Centre for Infectious Disease Control, National Institute for Public Health and Environment (RIVM), Bilthoven, the Netherlands

2. Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht (UMCU), Utrecht, the Netherlands

3. These authors contributed equally to this article and share last authorship

Abstract

We estimated vaccine effectiveness (VE) of SARS-CoV-2 Omicron XBB.1.5 vaccination against self-reported infection between 9 October 2023 and 9 January 2024 in 23,895 XBB.1.5 vaccine-eligible adults who had previously received at least one booster. VE was 41% (95% CI: 23–55) in 18–59-year-olds and 50% (95% CI: 44–56) in 60–85-year-olds. Sequencing data suggest lower protection against the BA.2.86 (including JN.1) variant from recent prior infection (OR = 2.8; 95% CI:1.2–6.5) and, not statistically significant, from XBB.1.5 vaccination (OR = 1.5; 95% CI:0.8–2.6).

Publisher

European Centre for Disease Control and Prevention (ECDC)

Reference19 articles.

1. Centers for Disease Control and Prevention (CDC). COVID-19 activity increases as prevalence of JN.1 variant continues to rise. Atlanta: CDC; 2024. Available from: https://www.cdc.gov/respiratory-viruses/whats-new/JN.1-update-2024-01-05.html

2. Covid-19: WHO adds JN.1 as new variant of interest.;Looi;BMJ,2023

3. Virological characteristics of the SARS-CoV-2 JN.1 variant.;Kaku;bioRxiv,2023

4. Protection of COVID-19 vaccination and previous infection against Omicron BA.1, BA.2 and Delta SARS-CoV-2 infections.;Andeweg;Nat Commun,2022

5. Sequencing directly from antigen-detection rapid diagnostic tests in Belgium, 2022: a gamechanger in genomic surveillance?;Rector;Euro Surveill,2023

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Enhancing COVID-19 Vaccination Awareness and Uptake in the Post-PHEIC Era: A Narrative Review of Physician-Level and System-Level Strategies;Vaccines;2024-09-11

2. Public Health and Economic Impact of Periodic COVID-19 Vaccination with BNT162b2 for Old Adults and High-Risk Patients in an Illustrative Prefecture of Japan: A Budget Impact Analysis;Infectious Diseases and Therapy;2024-09-10

3. Immune evasiveness of SARS-CoV-2 variants and vaccine selection;The Lancet Infectious Diseases;2024-09

4. Relative vaccine protection, disease severity, and symptoms associated with the SARS-CoV-2 omicron subvariant BA.2.86 and descendant JN.1 in Denmark: a nationwide observational study;The Lancet Infectious Diseases;2024-09

5. SARS-CoV-2 JN.1 variant: a short review;Monaldi Archives for Chest Disease;2024-08-30